Aster DM Healthcare announces Rs 120 Cr commitment for Oncology Radiation LINAC Centres

IMT News Desk
IMT News Desk
· 2 min read

Five state-of-the-art radiation therapy centres to be established across India

Aster DM Healthcare announced a major CSR initiative with Rs 120 crore investment to establish five advanced Oncology Radiation LINAC Centres across India, dedicated to supporting underprivileged cancer patients.

The first centre will be established in Wayanad, Kerala catering to the wider Malabar region, including neighbouring areas such as Gudalore and Gudalpet. The remaining centres will be developed in strategic locations including Bengaluru and other cities over the next three years, based on community needs and clinical feasibility.

The programme aims to provide free and subsidized high-quality radiation therapy to cancer patients from economically weaker sections who are unable to afford or continue life-saving treatment.

Dr Azad Moopen, Founder & Chairman, Aster DM Healthcare said, “This initiative reflects Aster’s deep commitment to making advanced cancer care accessible to all, especially underprivileged and underserved communities across India. By establishing five state-of-the-art radiation LINAC therapy centres, we aim to bridge critical gaps in oncology services and ensure that patients receive timely, lifesaving treatment closer to home. No one should be denied the chance to fight cancer with dignity, confidence, and hope. Through this effort, Aster reaffirms its mission of delivering high-quality, compassionate healthcare to every patient, regardless of their financial circumstances.”

A few key highlights of the initiative include a fully equipped modern centre with linear accelerators and allied facilities. The treatment will be provided completely free or at highly subsidised rates for patients with low income or those who fall under the below poverty line. Priority will be given to patients who have discontinued therapy due to financial constraints. The centres will be part of Aster Volunteers; the flagship global CSR program of Aster DM Healthcare focused on community health improvement and socio-economic development.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk